Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9707240 | 0.91 | LMNA (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL29693578 | 0.91 | LMNA (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL18210863 | 0.91 | LMNA (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL6038229 | 0.91 | LMNA (0.48) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL10351784 | 0.85 | PDE4A (0.54) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL21832157 | 0.85 | PDE4A (0.54) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL21832156 | 0.85 | PDE4A (0.54) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL5701179 | 0.85 | PDE4A (0.54) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL10351952 | 0.83 | TDP1 (0.55) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL10351108 | 0.83 | TDP1 (0.55) | LMNAL3MBTL1PDE4ATDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080219962-A1 | Method to Enhance the Bone Formation Activity of Bmp by Runx2 Acetylation | BIORUNX CO., LTD. (KR) | 2008-09-11 | — | — | US | claimed |
| EP-1833500-A1 | METHOD TO ENHANCE THE BONE FORMATION ACTIVITY OF BMP BY RUNX2 ACETYLATION | Biorunx Co., Ltd (KR) | 2007-09-19 | — | — | EP | claimed |
| WO-2006065075-A1 | METHOD TO ENHANCE THE BONE FORMATION ACTIVITY OF BMP BY RUNX2 ACETYLATION | BIORUNX CO. LTD. (KR) | 2006-06-22 | — | — | WO | claimed |
| EP-3328404-A1 | METHODS AND COMPOSITIONS FOR PRODUCING PANCREATIC BETA CELLS | The Regents of The University of California (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017019702-A1 | METHODS AND COMPOSITIONS FOR PRODUCING PANCREATIC BETA CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-02 | — | — | WO | disclosed |
| CN-101115495-B | Method to enhance the bone formation activity of bmp by RUNX2 acetylation | BIORUNX | 2011-06-22 | — | — | CN | disclosed |
| US-20080219962-A1 | Method to Enhance the Bone Formation Activity of Bmp by Runx2 Acetylation | BIORUNX CO., LTD. (KR) | 2008-09-11 | — | — | US | disclosed |
| CN-101115495-A | Method to enhance the bone formation activity of bmp by RUNX2 acetylation | BIORUNX (KR) | 2008-01-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080219962-A1 | Method to Enhance the Bone Formation Activity of Bmp by Runx2 Acetylation | BMP2, BMP1, BMP4 | LMNA 1822/4885L3MBTL1 3336/4885PDE4A 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.